周一，H.C. Wainwright分析师Andrew Fein将Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX )的目标价从之前的535美元上调至550美元，同时维持对该股的买入评级。根据 InvestingPro ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $430.00 to $433.00 in a research note released on Friday morning,Benzinga reports. The brokerage ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

当地时间1月30日， 福泰制药（Nasdaq: VRTX）宣布，美国食品药品监督管理局（FDA）已批准其口服非阿片类高选择性NaV1.8疼痛信号抑制剂JOURNAVX™（suzetrigine），用于治疗成人中度至重度急性疼痛。据福泰制药介绍，JOURNAVX是一种高效且耐受性良好的药物，无成瘾性证据，适用于所有类型的中重度急性疼痛。

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...